aILD care foundation research team, EdebFaculty of Medicine, Utrecht University, UtrechtcILD Center of Excellence, St. Antonius Hospital, NieuwegeindDepartment of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Science, Maastricht University, MaastrichteDepartment of Medical Psychology, St. Elisabeth-TweeSteden Hospital Tilburg, TilburgfDepartment of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands
Checking for direct PDF access through Ovid
Purpose of reviewFatigue is a problem experienced by many patients suffering from chronic diseases, including sarcoidosis patients. It has a substantial influence on patients’ quality of life (QoL). It is, therefore, important to properly assess fatigue with a valid and reliable measure. The Fatigue Assessment Scale (FAS) is the only validated self-reporting instrument classifying fatigue in sarcoidosis. The aim of this review was to examine the psychometric properties of the FAS and the diseases and languages in which it has been used. Studies among sarcoidosis patients were also reviewed in terms of outcomes.Recent findingsStudies were identified by searching the electronic bibliographic database Pubmed. Search terms used were: FAS and fatigue. Articles were included in the review if the FAS had been used to assess fatigue.ResultsSince its introduction, the FAS was used in 26 different diseases or conditions, including stroke, neurologic disorders, rheumatoid arthritis, idiopathic pulmonary fibrosis and sarcoidosis. Its reliability and validity have proved to be good. Unidimensionality has been established. So far, the FAS is available in 20 languages and widely used in sarcoidosis. Digital versions as well as PDFs of various languages are available online (www.wasog.org).SummaryThe FAS has good psychometric qualities for the diseases in which it has been examined, including sarcoidosis, and can be used in clinical practice. Healthcare workers can use the FAS to assess fatigue in the management, follow-up and clinical care programmes for their patients consistently across countries, as well as in clinical research.